Obesity is a strong risk factor for short-term mortality and adverse outcomes in Mexican patients with COVID-19: a national observational study

Abstract

Conflicting results have been obtained through meta-analyses for the role of obesity as a risk factor for adverse outcomes in patients with coronavirus disease-2019 (COVID-19), possibly due to the inclusion of predominantly multimorbid patients with severe COVID-19. Here, we aimed to study obesity alone or in combination with other comorbidities as a risk factor for short-term all-cause mortality and other adverse outcomes in Mexican patients evaluated for suspected COVID-19 in ambulatory units and hospitals in Mexico. We performed a retrospective observational analysis in a national cohort of 71 103 patients from all 32 states of Mexico from the National COVID-19 Epidemiological Surveillance Study. Two statistical models were applied through Cox regression to create survival models and logistic regression models to determine risk of death, hospitalisation, invasive mechanical ventilation, pneumonia and admission to an intensive care unit, conferred by obesity and other comorbidities (diabetes mellitus (DM), chronic obstructive pulmonary disease, asthma, immunosuppression, hypertension, cardiovascular disease and chronic kidney disease). Models were adjusted for other risk factors. From 24 February to 26 April 2020, 71 103 patients were evaluated for suspected COVID-19; 15 529 (21.8%) had a positive test for SARS-CoV-2; 46 960 (66.1%), negative and 8614 (12.1%), pending results. Obesity alone increased adjusted mortality risk in positive patients (hazard ratio (HR) = 2.7, 95% confidence interval (CI) 2.04–2.98), but not in negative and pending-result patients. Obesity combined with other comorbidities further increased risk of death (DM: HR = 2.79, 95% CI 2.04–3.80; immunosuppression: HR = 5.06, 95% CI 2.26–11.41; hypertension: HR = 2.30, 95% CI 1.77–3.01) and other adverse outcomes. In conclusion, obesity is a strong risk factor for short-term mortality and critical illness in Mexican patients with COVID-19; risk increases when obesity is present with other comorbidities.

Why should obese youth be prioritized in COVID-19 vaccination programs? A nationwide retrospective study

“…Although the association between obesity and COVID-19 severity has been evaluated in other high-quality studies, 4 , 14 , 15 , 16 our retrospective study covers the entire country of Brazil during the pre-vaccination period. By using a government database created exclusively for monitoring SARS, we leveraged the following: (1) a large sample size of hospitalized patients with laboratory-confirmed COVID-19; (2) information on comorbidities and BMI collected at the time of hospital admission, therefore simultaneously with the laboratory diagnosis of COVID-19; (3) the specific contribution of obesity, CVD, and diabetes to the risk of severe COVID-19, (4) stratification by BMI and age, and (5) analysis of ICU admission, ventilatory support, and death.…”

Association of Differences in Dietary Behaviours and Lifestyle with Self-Reported Weight Gain during the COVID-19 Lockdown in a University Community from Chile: A Cross-Sectional Study

“…There are currently no sufficiently proven interventions for COVID-19 that may decrease mortality and complication rates at every stage of disease. Comorbidities like obesity, hypertension and diabetes mellitus worsen the prognosis of the disease [ 38 , 39 , 40 , 41 ]. Furthermore, disruptions in the gut microbiome have been hypothesized to be associated with disease progression in COVID-19 [ 42 ].…”

COVID-19 patients with increasing age experience differential time to initial medical care and severity of symptoms

“…Also, our study is limited by the fact that we could not assess disease progression according to clinical criteria since parameters for staging patients are not captured in this dataset, and thus we used severity of symptoms (respiratory symptoms) as a correlate of disease severity at admission since respiratory symptoms are strongly associated with the risk of death and other adverse outcomes. The exclusion of patients with a negative RT-PCR for SARS-CoV-2 could have introduced bias in our study since a negative RT-PCR result does not necessarily imply the absence of the disease and we did not compare characteristics of patients with negative, positive and pending testing results, which have been shown to have different baseline and follow-up characteristics, as well as different associations with mortality risk in a previous study performed in Mexican ambulatory and hospitalised patients [ 21 ]. Furthermore, patients <20 and ≥80 years were likely underrepresented in our study due to lower testing rates in these age categories, which compromise validity of our findings.…”